{"changes":[],"country":"US","description":"Abcuro develops monoclonal antibodies that selectively deplete highly cytotoxic T and NK cells driving autoimmune disease and cancer. It targets patients with conditions such as inclusion body myositis and T/NK-cell lymphomas. Its lead antibody ulviprubart, now in late-stage trials, is built around precise KLRG1 targeting.","domain":"abcuro.com","employees":null,"founded":2018,"fundingTotalQuarantined":false,"githubOrg":null,"githubStars":null,"industry":"biotech","investors":["nea"],"lat":42.36324,"lng":-71.20151,"location":"Newton","name":"Abcuro","rounds":[{"amountQuarantined":false,"amountUsd":200000000,"currency":"USD","date":"2025-02-12","investors":["nea"],"leadInvestor":"nea","source":{"fact":"round","publisher":"vc-portfolio","retrievedAt":"2026-05-13","status":"attributed","url":null},"status":"attributed","type":"series-c","url":null}],"slug":"abcuro-com","sources":[{"fact":"round","publisher":"vc-portfolio","retrievedAt":"2026-05-13","status":"attributed","url":null},{"fact":"existence","publisher":"abcuro.com","retrievedAt":"2026-05-13","status":"self-reported","url":"https://abcuro.com"},{"fact":"description","publisher":"abcuro.com","retrievedAt":"2026-05-13","status":"self-reported","url":"https://abcuro.com"}],"stage":"series-b+","techStack":["PHP 7.4.33","WordPress 5.9.3","Apache HTTP Server","Yoast SEO 18.2","Genesis theme","jQuery Migrate 3.3.2","MySQL","jquery 3.6.0","apache"],"totalRaisedUsd":300000000,"updatedAt":"2026-05-13"}